scholarly journals Efficacy of SEBCLAIRA® Cream for Moderate Seborrhoeic Dermatitis on The Face as An Adjuvant Therapy (Randomised Clinical Trial, Double Blind)

2018 ◽  
Vol 2 (2) ◽  
pp. 54-60
Author(s):  
Inda Astri Aryani ◽  
Yulia Farida Yahya ◽  
Nina Roiana ◽  
Radema A Pranata
Keyword(s):  
Clinical Trial ◽  
Analogue Scale ◽  
Calcineurin Inhibitor ◽  
Severity Index ◽  
Randomised Clinical Trial ◽  
Double Blind Study ◽  
Double Blind ◽  
Seborrhoeic Dermatitis ◽  
The Face ◽  
The Mean

Background: Seborrhoeic dermatitis (SD) is a chronic papulosquamous inflammatory disease which resistant to medical treatment. Various treatment such as topical corticosteroid, antifungal and calcineurin inhibitor has been widely practiced and gives varying results Objective: Our objective was to compare the efficacy of Sebclaira® and topical hydrocortisone 2,5% for management of moderate SD on the face Methods: A randomised clinical trial, controlled, double blind study was performed for four weeks. We assessed the efficacy and side effects of these topical treatment. The severity of SD was evaluated using Seborrhea Area Severity Index-Facial (SASI-F) score. The severity of pruritus was evaluated using Visual Analogue Scale. Demographic characteristics, baseline SASI-F and VAS were recorded in the medical record. Results: A 34 patients (14 males, 20 females) with moderate SD on the face completed the four weeks study. The mean of SASI T2 and VAS score of the Sebclaira® group was significantly lower than Hydrocortisone 2.5% group with p = 0.000 and p = 0.000 respectively. Tolerance between Sebclaira® and Hydrocortisone 2.5% showed insignificant results (p = 1.000) Conclusions: The longer application of Sebclaira® was significantly more effective to improve moderate SD

The Effect of Three Desensitizing Agents on Dentin Hypersensitivity: A Randomized, Split-mouth Clinical Trial

2014 ◽  
Vol 39 (5) ◽  
pp. E186-E194 ◽  
Author(s):  
CRG Torres ◽  
TM Silva ◽  
BM Fonseca ◽  
ALLS Sales ◽  
P Holleben ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Analogue Scale ◽  
Tactile Stimulus ◽  
Multiple Comparisons ◽  
Dentin Hypersensitivity ◽  
Double Blind Study ◽  
Double Blind ◽  
Desensitizing Agents ◽  
Baseline Values

SUMMARY The aim of this study was to evaluate the efficacy of three desensitizing agents to provide relief to dentin hypersensitivity after one session in a four-week follow-up. Forty selected patients participated in a double-blind study following a split-mouth model. One application of the desensitizing agents (A, Admira Protect [Voco]; B, Bifluorid 12 [Voco]; and C, Colgate Pro-Relief in office [Colgate Palmolive]) was performed in three different quadrants for each patient. Each tooth was evaluated by tactile and evaporative stimuli, and the sensitivity response was measured using the Visual Analogue Scale. Evaluations were performed at baseline, immediately after treatment, and after one, two, three, and four weeks. The application of Kruskal-Wallis and Dunn multiple comparisons tests (5%) for both tactile and evaporative stimuli showed that all agents presented a significant desensitizing effect. In groups A and B this relief was maintained for four and three weeks, respectively, as measured by tactile stimulus and for four weeks with evaporative stimulus. The desensitizing effect for group C was maintained for two weeks for both tactile and evaporative stimuli. It is concluded that all desensitizing agents tested were effective in reducing sensitivity compared to baseline values. One application of Admira Protect and Bifluorid 12 presented a longer-lasting desensitizing effect than did Colgate Pro-Relief (applied in the office) on both tactile and evaporative stimuli.

The Effect of Silicol Gel Compared with Placebo on Papulopustular Acne and Sebum Production. A Double-Blind Study

1996 ◽  
Vol 24 (4) ◽  
pp. 340-344 ◽  
Author(s):  
A Lassus
Keyword(s):  
Placebo Group ◽  
Treated Group ◽  
Double Blind Study ◽  
Concomitant Treatment ◽  
Double Blind ◽  
Area 5 ◽  
Significant Difference ◽  
The Face ◽  
Sebum Production ◽  
The Mean

Altogether 30 patients (19 females and 11 males), mean age 19 years, were divided randomly into two groups. All patients had chronic papulopustular acne of the face. A total of 15 patients were treated topically with Silicol gel for 20 min twice daily for 6 weeks and the remaining 15 patients were treated with a placebo gel in a similar fashion. A clinical evaluation was carried out at baseline, and after 2, 4 and 6 weeks of treatment. The clinical variables evaluated were as follows: number of comedones, papules, pustules and cysts on a standard area of the left cheek (area 5 × 5 cm) and measurement of sebum production on the same area by the use of Sebumeter SM 810 PC (Courage and Khazaka, Ltd, Germany). No concomitant treatment was allowed during the study period. One patient using Silicol gel withdrew after 2 weeks of treatment because of severe irritation of the facial skin, leaving 29 patients who could be evaluated. In the active group, the number of comedones decreased from a mean of 48.5 to 15.1 after 6 weeks of treatment. The corresponding figures for papules were 10.7 and 1.0, for pustules 6.8 and 0, and for cysts 0.6 and 0. In the placebo group no improvement could be observed. There was a highly significant difference in efficacy between the two groups ( P < 0.001) in favour of the actively treated group. The mean sebum index was 193 at baseline and 88 after 6 weeks. Correspondingly, in the placebo group the mean sebum index at baseline was 187 and after 6 weeks 179. This difference between the two groups was also statistically significant ( P < 0.001). After a short follow-up period (3 months) no deterioration was observed in the 14 ‘active’ patients, showing either complete cure or improvement.

scholarly journals Evaluation of the efficacy of a topical chamomile-pumpkin oleogel for the treatment of plaque psoriasis: an intra-patient, double-blind, randomized clinical trial

2018 ◽  
Vol 5 (11) ◽  
pp. 2811-2819
Author(s):  
Sima Kolahdooz ◽  
Mehrdad Karimi ◽  
Nafiseh Esmaili ◽  
Arman Zargaran ◽  
Gholamreza Kordafshari ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Side Effects ◽  
Randomized Clinical Trial ◽  
Plaque Psoriasis ◽  
Severity Index ◽  
Double Blind ◽  
The Mean ◽  
Psoriasis Severity

Background: Plaque psoriasis is a chronic inflammatory skin disease. Conventional treatments of psoriasis are not completely effective. In addition, unwanted side effects limit their long-term use. In this regard, developing new natural treatments with fewer side effects could be an alternative option. This study was designed to evaluate the efficacy and safety of topical chamomile-pumpkin oleogel (ChP) in treating plaque psoriasis. Methods: A total of 40 patients with mild-to-moderate plaque psoriasis were enrolled in this intra-patient, double-blind, block-randomized clinical trial. In each patient, bilateral symmetrical plaques were treated with ChP or placebo twice daily for four weeks. For clinical assessment, the Psoriasis Severity Index (PSI) and the Physician's Global Assessment (PGA) scale were evaluated at baseline and after the treatment. At the end of the study, patients' satisfaction with the treatment was evaluated using a visual analog scale (VAS) ranging from 0 to 10. For safety assessment, all treatment-related side effects were recorded. Results: Thirty-seven subjects (20 female, 17 male; age 20–60 years) completed the study. The mean decreases in the PSI score in the ChP group (4.09 +/- 2.24) were significantly (p = 0.000) greater than the placebo group (0.48 +/- 1.39). According to the PGA results, 13/37 (35%) of the ChP-treated plaques could achieve marked to complete improvement compared to 0% in the placebo group. Three patients dropped out from the study due to worsening of bilateral plaques during the first week of trial. Conclusion: Our results suggest that topically applied ChP could provide a safe and effective complementary option for psoriasis plaque management. IRCT registration code: IRCT2016092830030N1.  

scholarly journals A Randomized Double-blind Study on the Efficacy of 20% VCO Cream versus a Commercial Emollient for Atopic Dermatitis in Children

2020 ◽  
Vol 54 (2) ◽  
Author(s):  
Gina C. Castro ◽  
Jovencio G. Apostol
Keyword(s):  
Atopic Dermatitis ◽  
Skin Barrier ◽  
Severity Index ◽  
Study Groups ◽  
Double Blind Study ◽  
Double Blind ◽  
Product Usage ◽  
Intention To Treat ◽  
The Mean ◽  
Treat Analysis

Objective. To assess the effects of a formulated 20% VCO cream on symptoms of atopic dermatitis in children relative to a commercial emollient with skin barrier protective property indicated for dry, itchy skin. Methods. In a randomized, double-blind, pilot study, pediatric patients with atopic dermatitis according to the modified Hanifin and Rajka criteria were enrolled and assigned to use either formulated VCO cream or commercial emollient. Treatments were applied twice daily for four (4) weeks. Outcome measures were investigator- and patientassessed clinical efficacy based on Severity Scoring of Atopic Dermatitis (SCORAD) severity index, and incidences of documented adverse events.Results. Twenty-nine patients were recruited in the study and in an intention-to-treat analysis, mean SCORAD indices were reduced by 41.79% and 29.77% in the VCO cream group and commercial emollient group, respectively. Both study groups showed significant reduction in the mean subjective SCORAD index relating to pruritus and sleep loss. Mean objective SCORAD index, based on intensity items and total surface with eczema, was also significantly improved in the VCO cream group after four weeks of product usage. The study products were generally well-tolerated, with minor adverse events reported for the VCO cream group. Conclusion. Results of the study suggest that application of VCO at 20% in a cream formulation is more effective than the tested commercial emollient in alleviating symptoms of AD in children.

Sign in / Sign up

Export Citation Format

Share Document